PXVX 0200

Drug Profile

PXVX 0200

Alternative Names: Cholera vaccine CVD 103-HgR; Cholera vaccine live attenuated - PaxVax; CVD 103-HgR; CVD HgR 103 vaccine; CVD-103; Mutacol; Mutacol-Berna; Orochol; Orochol-Berna; PXVX-0200; Vaxchora

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Berna Biotech; Center for Vaccine Development
  • Developer Berna Biotech; Center for Vaccine Development; PaxVax
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera

Most Recent Events

  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 21 Jul 2017 PaxVax plans a phase IV trial for Cholera in USA (In Childrens) in July 2017 (NCT03220737)
  • 24 Oct 2016 Launched for Cholera (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top